» Articles » PMID: 35632499

Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron

Overview
Date 2022 May 28
PMID 35632499
Authors
Affiliations
Soon will be listed here.
Abstract

In this report, we mechanistically reveal how the Variant of Concern (VOC) SARS-CoV-2 Omicron (B.1.1.529) escapes neutralizing antibody responses, by physio-chemical characterization of this variant in comparison to the wild-type Wuhan and the Delta variant (B.1.617.2). Convalescent sera, as well as sera obtained from participants who received two or three doses of mRNA vaccines (Moderna-mRNA-1273 or Pfizer-BNT162b2), were used for comparison in this study. Our data demonstrate that both Delta, as well as Omicron variants, exhibit a higher affinity for the receptor ACE2, facilitating infection and causing antibody escape by receptor affinity (affinity escape), due to the reduced ability of antibodies to compete with RBD-receptor interaction and virus neutralization. In contrast, only Omicron but not the Delta variant escaped antibody recognition, most likely because only Omicron exhibits the mutation at E484A, a position associated with reduced recognition, resulting in further reduced neutralization (specificity escape). Nevertheless, the immunizations with RNA-based vaccines resulted in marked viral neutralization in vitro for all strains, compatible with the fact that Omicron is still largely susceptible to vaccination-induced antibodies, despite affinity- and specificity escape.

Citing Articles

COVID-19 Variants and Vaccine Development.

Zhao Z, Bashiri S, Ziora Z, Toth I, Skwarczynski M Viruses. 2024; 16(5).

PMID: 38793638 PMC: 11125726. DOI: 10.3390/v16050757.


Automated antigen assays display a high heterogeneity for the detection of SARS-CoV-2 variants of concern, including several Omicron sublineages.

Osterman A, Krenn F, Iglhaut M, Badell I, Lehner A, Spath P Med Microbiol Immunol. 2023; 212(5):307-322.

PMID: 37561226 PMC: 10501957. DOI: 10.1007/s00430-023-00774-9.


A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells.

Kegler A, Drewitz L, Arndt C, Daglar C, Rodrigues Loureiro L, Mitwasi N Front Immunol. 2023; 14:1204543.

PMID: 37383226 PMC: 10293748. DOI: 10.3389/fimmu.2023.1204543.


Correlating the differences in the receptor binding domain of SARS-CoV-2 spike variants on their interactions with human ACE2 receptor.

Mahalingam G, Arjunan P, Periyasami Y, Dhyani A, Devaraju N, Rajendiran V Sci Rep. 2023; 13(1):8743.

PMID: 37253762 PMC: 10227802. DOI: 10.1038/s41598-023-35070-2.


A computationally designed ACE2 decoy has broad efficacy against SARS-CoV-2 omicron variants and related viruses in vitro and in vivo.

Havranek B, Lindsey G, Higuchi Y, Itoh Y, Suzuki T, Okamoto T Commun Biol. 2023; 6(1):513.

PMID: 37173421 PMC: 10177734. DOI: 10.1038/s42003-023-04860-9.


References
1.
Callaway E . Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887):21. DOI: 10.1038/d41586-021-03552-w. View

2.
Bachmann M, Mohsen M, Zha L, Vogel M, Speiser D . SARS-CoV-2 structural features may explain limited neutralizing-antibody responses. NPJ Vaccines. 2021; 6(1):2. PMC: 7782831. DOI: 10.1038/s41541-020-00264-6. View

3.
Augusto G, Mohsen M, Zinkhan S, Liu X, Vogel M, Bachmann M . In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. Allergy. 2021; 77(1):111-117. PMC: 8652796. DOI: 10.1111/all.15065. View

4.
Dejnirattisai W, Huo J, Zhou D, Zahradnik J, Supasa P, Liu C . SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell. 2022; 185(3):467-484.e15. PMC: 8723827. DOI: 10.1016/j.cell.2021.12.046. View

5.
Mannar D, Saville J, Zhu X, Srivastava S, Berezuk A, Tuttle K . SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science. 2022; 375(6582):760-764. DOI: 10.1126/science.abn7760. View